Hemophilia is an inherited single gene disorder with an incidence of 1 per 10,000 births; affecting men (women are only carriers) in which the blood doesn't clot normally. With more than two lakh cases, India is home to the second largest population of people with Hemophilia. Blood contains many proteins called clotting factors that help stop bleeding. People with hemophilia (PwH) have low levels of either factor VIII (8) or factor IX (9). The severity of hemophilia that a person has is determined by the amount of factor in the blood. The lower the amount of the clotting factor, the more likely it is that bleeding will occur which can lead to serious health problems. This means the person tends to bleed for a longer time after an injury, and they are more susceptible to internal bleeding. This bleeding can be fatal if it occurs within a vital organ.2
Hemlibra is the standard of care for the treatment of people with hemophilia A. Hemlibra has been approved in India for Hemophilia A with or without factor VIII inhibitors. It is indicated as a prophylactic (preventive) treatment to prevent or reduce the frequency of bleeding episodes for patients across all age groups; Hemlibra is also the first subcutaneous drug for hemophilia A that you can self administer as an injection under your skin. There are several possible dosing schedules, including weekly, every two weeks, or every four weeks intended to allow patients and their physicians to choose the option that’s right for them, based on their lifestyle and preferences.
Hemlibra has been studied in one of the largest pivotal clinical trial programmes in hemophilia A with and without factor VIII inhibitors. Hemlibra is approved in more than 100 countries worldwide and since its initial FDA approval, more than 15,000 people have received Hemlibra globally.
I understand the following:
The information contained in this Letter is for the sole purpose of use and knowledge of Healthcare Professionals (HCPs) Only.
If any Individual other than HCPs access the information contained in this Letter and act thereon, then Roche will not be liable for any consequences in relation thereto.
Patients and their relatives should not access the information contained in this Letter. They are advised to consult their treating physicians.
I hereby confirm that I am a Healthcare Professional and agree to the terms and conditions mentioned above.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. This website is neither intended nor designed to record or report adverse event information. If you have a suspected side effect or problem to report regarding one of our products, visit us at